Cytokinetics Terminates Collaboration Agreement with Amgen for Omecamtiv Mecarbil

Cytokinetics, Incorporated, a biopharmaceutical company focused on cardiovascular and pulmonary muscle contractility, has received written notice of termination from Amgen Inc. of their Collaboration and Option Agreement for the discovery, development, and commercialization of novel small molecule therapeutics, including omecamtiv mecarbil, a cardiac myosin activator. This termination, effective on May 20, 2021, marks the end of their partnership, with Amgen having held exclusive worldwide rights to develop and commercialize omecamtiv mecarbil and related compounds. Cytokinetics will now assume these rights and obligations, including research, development, and commercialization activities.

Key Takeaways:

• Cytokinetics and Amgen have terminated their Collaboration and Option Agreement, effective on May 20, 2021.
• Amgen had exclusive worldwide rights to develop and commercialize omecamtiv mecarbil, while Cytokinetics held specified development and commercial participation rights.
• Upon termination, Cytokinetics will assume research, development, and commercialization rights for omecamtiv mecarbil and related compounds.
• Amgen will hand over to Cytokinetics certain ongoing development activities, regulatory filings, data, and other information, as well as transfer inventory of compounds and relevant third-party manufacturing agreements.
• The Agreement was filed with the SEC as Exhibit 10.63 to Cytokinetics' Annual Report on Form 10-K filed on March 12, 2007, and Exhibit 10.49 to Cytokinetics' Annual Report on Form 10-K filed on March 7, 2019.

Statistics:

• The Collaboration and Option Agreement was signed on December 29, 2006.
• The agreement was initially filed with the SEC on [no date specified].
• Cytokinetics holds specified development and commercial participation rights under the Agreement.
• Amgen had the discretion to elect whether to pursue or abandon the development of omecamtiv mecarbil.
• Cytokinetics will retain exclusive and non-exclusive licenses to certain intellectual property rights.

Sources:

• UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 8-K _____________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 20, 2020
• Cytokinetics, Incorporated, 280 East Grand Avenue, South San Francisco, California 94080, (650) 624-3000
• Amgen Inc. (Exact Name of Registrant as Specified in Charter)
• Exhibit 10.63 to Cytokinetics' Annual Report on Form 10-K filed with the SEC on March 12, 2007
• Exhibit 10.49 to Cytokinetics' Annual Report on Form 10-K filed with the SEC on March 7, 2019